XFRA:CX5N CytRx Corp Quarterly Report 10-Q Filing - 6/30/2012

Effective Date 6/30/2012

XFRA:CX5N (CytRx Corp): Fair Value Estimate
Premium
XFRA:CX5N (CytRx Corp): Consider Buying
Premium
XFRA:CX5N (CytRx Corp): Consider Selling
Premium
XFRA:CX5N (CytRx Corp): Fair Value Uncertainty
Premium
XFRA:CX5N (CytRx Corp): Economic Moat
Premium
XFRA:CX5N (CytRx Corp): Stewardship
Premium
 
form10q2q12.htm




UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 10-Q

R
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the quarterly period ended June 30, 2012
 
OR
 
£
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the transition period from  ___________________  to ___________________               


Commission file number 0-15327

CytRx Corporation
(Exact name of Registrant as specified in its charter)

Delaware
58-1642740
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification No.)
 
11726 San Vicente Blvd., Suite 650
Los Angeles, CA
90049
(Address of principal executive offices)
(Zip Code)
 
(310) 826-5648
(Registrant’s telephone number, including area code)
 
Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes þ     No o
 
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes þ  No o
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
 
Large accelerated filer o
Accelerated filer þ
Non-accelerated filer o
Smaller reporting company o
 
(Do not check if a smaller reporting company)
 
Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12(b)-2 of the Exchange Act).  Yes o     No þ
 
Number of shares of CytRx Corporation common stock, $.001 par value, outstanding as of August 8, 2012: 21,206,367 shares exclusive of treasury shares.
 
 



 
 

 


CYTRX CORPORATION

FORM 10-Q

TABLE OF CONTENTS


 
Page
PART I. — FINANCIAL INFORMATION
 
Item 1. Financial Statements
2
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
10
Item 3. Quantitative and Qualitative Disclosures About Market Risk
14
Item 4. Controls and Procedures
15
   
PART II. — OTHER INFORMATION
 
Item 6. Exhibits
15
   
SIGNATURES
16
   
INDEX TO EXHIBITS
17
 
 
 

 
 
1

 


PART I — FINANCIAL INFORMATION

 
Item 1. — Financial Statements
 
CYTRX CORPORATION
CONDENSED BALANCE SHEETS
(Unaudited)

 
 
June 30, 2012
   
December 31, 2011
 
ASSETS
           
Current assets:
           
Cash and cash equivalents
  $ 11,859,009     $ 17,988,590  
Marketable securities
    15,067,770       18,057,672  
Receivable
    20,758       175,704  
Interest receivable
    22,171       41,275  
Prepaid expenses and other current assets
    918,821       1,017,799  
Total current assets
    27,888,529       37,281,040  
Equipment and furnishings, net
    321,102       266,335  
Goodwill
    183,780       183,780  
Other assets
    119,921       123,268  
Total assets
  $ 28,513,332     $ 37,854,423  
LIABILITIES AND STOCKHOLDERS’ EQUITY
               
                 
Accounts payable
  $ 2,232,148     $ 2,074,463  
Accrued expenses and other current liabilities
    5,403,039       4,786,956  
Warrant liabilities
    19,155,292       6,738,934  
Total current liabilities
    26,790,479       13,600,353  
Stockholders’ equity (2011 restated to reflect a 1-7 reverse common stock split, see Note 1):
               
Preferred Stock, $.01 par value, 5,000,000 shares authorized, including 25,000 shares of Series A Junior Participating Preferred Stock; no shares issued and outstanding
           
Common stock, $.001 par value, 250,000,000 shares authorized;  21,296,913 shares issued and outstanding at June 30, 2012 and 21,294,413 shares issued and outstanding at December 31, 2011
    21,296       21,294  
Additional paid-in capital
    238,318,443       237,452,308  
Treasury stock, at cost (90,546 shares)
    (2,279,238 )     (2,279,238 )
Accumulated deficit
    (234,337,648 )     (210,940,294 )
Total stockholders’ equity
    1,722,853       24,254,070  
Total liabilities and stockholders’ equity
  $ 28,513,332     $ 37,854,423  



The accompanying notes are an integral part of these condensed financial statements.


 
2

 


CYTRX CORPORATION
CONDENSED STATEMENTS OF OPERATIONS
(Unaudited)


   
Three Months Ended
June 30,
   
Six Months Ended
June 30,
 
   
2012
   
2011
   
2012
   
2011
 
Revenue:
                       
License revenue
  $     $ 150,000     $     $ 150,000  
                                 
Expenses:
                               
Research and development
    2,686,465       1,886,652       7,087,980       6,707,360  
General and administrative
    2,091,856       2,026,602       4,006,572       4,174,061  
      4,778,321       3,913,254       11,094,552       10,881,421  
                                 
Loss before other income (expense)
    (4,778,321 )     (3,763,254 )     (11,094,552 )     (10,731,421 )
Other income (expense):
                               
Interest income
    27,547       50,270       63,005       105,699  
Other income, net
    16,491       15,619       50,551       52,650  
(Loss) gain on warrant derivative liabilities
    (8,528,192 )     577,290       (12,416,358 )     1,177,762  
Loss before provision for income taxes
    (13, 262,475 )     (3,120,075 )     (23,397,354 )     (9,395,310 )
Provision for income taxes
                       
Net loss
  $ (13,262,475 )   $ (3,120,075 )   $ (23,397,354 )   $ (9,395,310 )
                                 
Other comprehensive income (net of tax)
                               
Unrealized gain on available-for-sale securities
 
­­  —
      379,260             379,260  
                                 
Comprehensive loss
  $ (13,262,475 )   $ (2,740,815 )   $ (23,397,354 )   $ (9,016,050 )
                                 
Basic and diluted  net loss per share
  $ (0.63 )   $ (0.20 )   $ (1.10 )   $ (0.60 )
                                 
Basic and diluted weighted-average shares outstanding
    21,204,499       15,603,867       21,203,754       15,603,812  


The accompanying notes are an integral part of these condensed financial statements

 
3

 


CYTRX CORPORATION
CONDENSED STATEMENTS OF CASH FLOWS
(Unaudited)

   
 
Six Months Ended June 30,
 
 
 
2012
   
2011
 
Cash flows from operating activities:
           
Net loss
  $ (23,397,354 )   $ (9,395,310 )
Adjustments to reconcile net loss to net cash used in operating activities:
               
Depreciation and amortization
    52,875       45,670  
Retirement of fixed assets
    4,360       4,372  
Stock option and warrant expense
    858,937       827,987  
Fair value adjustment on warrant liabilities
    12,416,358       (1,177,762 )
Changes in assets and liabilities:
               
Receivable
    154,946       151,061  
Interest receivable
    19,105       12,290  
Prepaid expenses and other current assets
    102,323       (564,867 )
Income taxes recoverable
          519,158  
Accounts payable
    93,663       405,858  
Accrued expenses and other current liabilities
    616,083       1,466,170  
Net cash used in operating activities
    (9,078,704 )     (7,705,373 )
                 
Cash flows from investing activities:
               
Net proceeds from sale of marketable securities
    2,989,902       1,491,241  
Proceeds from sale of unconsolidated subsidiary shares
          6,938,603  
Purchases of equipment and furnishings
    (47,979 )     (25,725 )
Net cash provided by investing activities
    2,941,923       8,404,119  
                 
Cash flows from financing activities:
    7,200        
Net proceeds from exercise of stock options
    7,200        
                 
Net increase (decrease) in cash
    (6,129,581 )     698,746  
Cash  at beginning of period
    17,988,590       6,324,430  
Cash  at end of period
  $ 11,859,009     $ 7,023,176  
                 
Supplemental disclosure of cash flow information:
               
    Fixed assets purchased on credit
  $ 64,022        
Cash received during the period as interest income
  $ 82,110     $ 117,988  

 
The accompanying notes are an integral part of these condensed financial statements.


 
4

 

NOTES TO CONDENSED FINANCIAL STATEMENTS
 
June 30, 2012
(Unaudited)

1.  Description of Company and Basis of Presentation
 
CytRx Corporation (“CytRx” or the “Company”) is a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, specializing in oncology. CytRx’s oncology pipeline currently consiste of two programs in clinical development for cancer indications: aldoxorubicin (formerly known as INNO-206) and tamibarotene. With its tumor-targeted doxorubicin conjugate aldoxorubicin, CytRx has initiated an international Phase 2b clinical trial as a treatment for soft tissue sarcomas, has completed its Phase 1b/2 clinical trial primarily in the same indication, recently initiated a Phase 2 trial for patients with advanced pancreatic ductual adenocarcinomas, and plans to meet with the FDA in the second half of 2012 to discuss a potential Phase 3 pivotal trial as a therapy for patients with soft tissue sarcomas whose tumors have progressed following treatment with chemotherapy. Tamibarotene is being tested in a double-blind, placebo-controlled, international Phase 2b clinical trial in patients with non-small-cell lung cancer, and is in a Phase 2 clinical trial as a treatment for acute promyelocytic leukemia (APL). The Company also has completed its evaluation of a third drug candidate, bafetinib, in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic lymphocytic leukemia (B-CLL), and plans to seek a partner for further development of bafetinib.
 
The accompanying condensed financial statements at June 30, 2012 and for the three-month and six-month periods ended June 30, 2012 and 2011, respectively, are unaudited, but include all adjustments, consisting of normal recurring entries, that management believes to be necessary for a fair presentation of the periods presented. Prior period figures have been reclassified, wherever necessary, to conform to current presentation. Interim results are not necessarily indicative of results for a full year. Balance sheet amounts as of December 31, 2011 have been derived from the Company’s audited financial statements as of that date.
 
The financial statements included herein have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. The financial statements should be read in conjunction with the Company’s audited financial statements contained in its Annual Report on Form 10-K for the year ended December 31, 2011. The Company’s operating results will fluctuate for the foreseeable future. Therefore, period-to-period comparisons should not be relied upon as predictive of the results in future periods.
 
Effective May 15, 2012, the Company completed a 1-for-7 reverse stock split of the Company’s outstanding shares of common stock; no change was made to the per-share par value per share of the common stock or to the number of shares of authorized common stock. All share and per share amounts in the accompanying consolidated financial statements have been adjusted to reflect the reverse stock split as if it had occurred at the beginning of the earliest period presented.
 
2.  Recent Accounting Pronouncements
 
In June 2011, the Financial Accounting Standards Board (“FASB”) issued a final standard, requiring entities to present net income and other comprehensive income in either a single continuous statement or in two separate, but consecutive, statements of net income and other comprehensive income. The new standard eliminates the option to present items of other comprehensive income in the statement of changes in equity. The new requirements do not change which components of comprehensive income are recognized in net income or other comprehensive income, or when an item of other comprehensive income must be reclassified to net income. Also, earnings per share computations do not change. The new requirements are effective for interim and annual periods beginning after December 15, 2011, with early adoption permitted. Full retrospective application is required. The adoption of this accounting standard did not have an impact on the Company’s consolidated financial statements.
 
In May 2011, the FASB issued ASU 2011-04, Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and International Financial Reporting Standard (“IFRS”), to converge fair value measurement and disclosure guidance in U.S. GAAP with the guidance in the International Accounting Standards Board’s (“IASB”) concurrently issued IFRS 13, Fair Value Measurement. The amendments in ASU 2011-04 do not modify the requirements for when fair value measurements apply; rather, they generally represent clarifications on how to measure and disclose fair value under ASC 820, Fair Value Measurement. The amendments in the ASU 2011-04 were effective prospectively for interim and annual periods beginning after December 15, 2011. Adoption of this standard did not have a material impact on the Company’s consolidated financial statements.
 
3. Marketable Securities
 
The Company held $15.1 million of marketable securities at June 30, 2012.  The Company has classified these investments as available for sale.  These investments are comprised of federally insured certificates of deposit as follows: $5.1 million with a maturity date of July 12, 2012; $7.0 million with a maturity date of October 4, 2012; and $3.0 million with a maturity date of March 28, 2013.

 
5

 
 
4.  Investment in ADVENTRX Pharmaceuticals
 
On April 8, 2011, ADVENTRX Pharmaceuticals completed its acquisition of SynthRx, Inc., in which the Company held a 19.1% interest. In the transaction, the Company received approximately 126,000 shares of common stock of ADVENTRX, which it sold on October 11, 2011 for approximately $112,200.  In April 2012, the Company received an additional 38,000 shares of common stock of ADVENTRX that had been held in an escrow established in connection with the acquisition, which shares were subsequently sold for approximately $18,000.  If all of the development milestones under the acquisition agreement were to be achieved, the Company also would be entitled to receive up to 2.9 million additional ADVENTRX shares. The Company treated these shares as assets “available for sale”.
 
5. Basic and Diluted Net Loss Per Common Share
 
Basic and diluted net loss per common share is computed based on the weighted-average number of common shares outstanding. Common share equivalents (which consist of options and warrants) are excluded from the computation of diluted net loss per common share where the effect would be anti-dilutive.  Common share equivalents that could potentially dilute basic earnings per share in the future, and which were excluded from the computation of diluted loss per share, totaled 1.0 million for the three-month and six-month periods ended June 30, 2012, and 1.4 million and 0.5 million shares, respectively, for the three-month and six-month periods ended June 30, 2011.
 
6. Warrant Liabilities
 
Liabilities measured at market value on a recurring basis include warrant liabilities resulting from the Company’s past equity financing, including the underwritten public offering that closed on August 1, 2011.  In accordance with ASC 815-40, Derivatives and Hedging – Contracts in Entity’s Own Equity (“ASC 815-40”), the warrant liabilities are being marked to market until they are completely settled.  The warrants are valued using the Black-Scholes method, using assumptions consistent with our application of ASC 505-50, Equity-Based Payments to Non-Employees (“ASC 505-50”).  The gain or loss resulting from the marked to market calculation is shown on the Consolidated Statements of Operations as (Loss) Gain on warrant derivative liability. The Company recognized a (loss) gain of ($8.5 million) and $0.6 million for the three-month periods ended June 30, 2012 and 2011, respectively, and ($12.4 million) and $1.2 million for the six-month periods ended June 30, 2012 and 2011, respectively.
 
7.  Stock Based Compensation
 
The Company has a 2000 Long-Term Incentive Plan under which 1.4 million shares of common stock were originally reserved for issuance.  As of June 30, 2012, there were approximately 1.0 million shares subject to outstanding stock options. This plan expired on August 6, 2010, and thus no further shares are available for future grant under this plan.
 
The Company also has a 2008 Stock Incentive Plan under which 10.0 million shares of common stock were originally reserved for issuance.  The number of shares reserved for issuance under the 2008 Plan was then fixed at 5.0 million shares, after giving effect to the 1-for-7 reverse stock split implemented on May 15, 2012.  As of June 30, 2012, there were 0.9 million shares subject to outstanding stock options and 4.1 million shares available for future grant under this plan.
 
The Company has adopted the provisions of ASC 718, Compensation-Stock Compensation, which requires the measurement and recognition of compensation expense for all stock-based awards made to employees.
 
For stock options and stock warrants paid in consideration of services rendered by non-employees, the Company recognizes compensation expense in accordance with the requirements of ASC 505-50.
 
Non-employee option grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period, the value of these options, as calculated using the Black-Scholes option-pricing model, is determined, and compensation expense recognized or recovered during the period is adjusted accordingly. Since the fair market value of options granted to non-employees is subject to change in the future, the amount of the future compensation expense is subject to adjustment until the common stock options are fully vested.
 

 
6

 

  The following table sets forth the total stock-based compensation expense resulting from stock options and warrants included in the Company’s unaudited interim statements of operations:
 
   
Three Months Ended June 30,
   
Six Months Ended June 30,
 
   
2012
   
2011
   
2012
   
2011
 
Research and development — employee
  $ 98,242     $ 87,890     $ 193,366     $ 171,321  
General and administrative — employee
    263,007       343,682       437,079       541,274  
Total employee stock-based compensation
  $ 361,249     $ 431,572     $ 630,445     $ 712,595  
                                 
Research and development — non-employee
  $     $ 19,576     $     $ 41,484  
General and administrative — non-employee
    176,074       42,908       228,492       88,305  
Total non-employee stock-based compensation
  $ 176,074     $ 62,484     $ 228,492     $ 129,789  

During the six-month period ended June 30, 2012, the Company issued stock options to purchase 53,502 shares of its common stock. The fair value of the stock options granted in the current six-month period was estimated using the Black-Scholes option-pricing model, based on the following assumptions:
 
   
Six Months Ended June 30, 2012
   
Six Months Ended June 30, 2011
 
Risk-free interest rate
    1.54 %     2.13 %
Expected volatility
    89.7% - 97.7 %     87.69 %
Expected lives (years)
    6 - 10       10  
Expected dividend yield
    0.00 %     0.00 %

The Company’s computation of expected volatility is based on the historical daily volatility of its publicly traded stock. For option grants issued during the six-month period ended June 30, 2012, the Company used a calculated volatility for each grant. The Company uses historical information to compute expected lives. In the six-month period ended June 30, 2012, the contractual term of the options granted was ten years and the Company used between six and ten years as the expected life. The dividend yield assumption of zero is based upon the fact the Company has never paid cash dividends and presently has no intention of paying cash dividends. The risk-free interest rate used for each grant is equal to the U.S. Treasury rates in effect at the time of the grant for instruments with a similar expected life. Based on historical experience, for the six-month period ended June 30, 2012, the Company has estimated an annualized forfeiture rate of 14% for options granted to its employees, 2% for options granted to senior management and 0% for options granted to directors and non-employees. For the comparative six-month period ended June 30, 2011, the Company had estimated an annualized forfeiture rate of 13% for options granted to its employees, 2% for options granted to senior management and 0% for options granted to directors and non-employees. Compensation costs will be adjusted for future changes in estimated forfeitures. The Company will record additional expense if the actual forfeitures are lower than estimated and will record a recovery of prior expense if the actual forfeiture rates are higher than estimated. No amounts relating to employee stock-based compensation have been capitalized.
 
As of June 30, 2012, there remained approximately $1.2 million of unrecognized compensation expense related to unvested stock options granted to current and former employees, directors and consultants, to be recognized as expense over a weighted-average period of 1.09 years. Presented below is the Company’s stock option activity:
 
 
 
Six Months Ended June 30, 2012
 
 
 
 
Number of Options (Employees)
   
Number of Options (Non-Employees)
   
Total Number of Options
   
Weighted-Average Exercise Price
 
Outstanding at January 1, 2012
    1,763,923       143,572       1,907,495     $ 6.06  
Granted
    53,502             53,502     $ 2.77  
Exercised
    (2,500 )           (2,500 )   $ 2.88  
Forfeited or expired
    (26,384 )           (26,384 )   $ 4.97  
Outstanding at June 30, 2012
    1,788,541       143,572       1,932,113     $ 5.99  
Options exercisable at June 30, 2012
    1,238,545       125,715       1,364,260     $ 6.94  
                                 


 
7

 
A summary of the unvested stock options as of June 30, 2012, and changes during the six-month period then ended, is presented below:
 
   
Number of Options (Employees)
   
Number of Options (Non-Employees)
   
Total Number of Options
   
Weighted-Average Grant Date Fair Value per Share
 
Non-vested at January 1, 2012
    693,504       17,857       711,361     $ 3.28  
Granted
    53,502             53,502     $ 2.32  
Forfeited or expired
    (26,384 )           (26,384 )   $ 3.88  
Vested
    (173,181 )           (173,181 )   $ 3.26  
Non-vested at June 30, 2012
    547,441       17,857       565,298     $ 3.18  

The following table summarizes significant ranges of outstanding stock options under the Company’s plans at June 30, 2012:
 
Range of Exercise Prices
   
Number of Options
   
Weighted-Average Remaining Contractual Life (years)
   
Weighted-Average Exercise Price
   
Number of Options Exercisable
   
Weighted-Average Contractual Life
   
Weighted-Average Exercise Price
 
$ 1.96 - 3.00       648,768       8.83     $ 2.29       245,220       8.83     $ 2.46  
$ 3.01 –7.00       204,942       5.88     $ 5.40       195,680       5.88     $ 5.39  
$ 7.01 –8.50       946,117       5.64     $ 7.66       791,074       5.64     $ 7.74  
$ 8.51 – 32.55       132,286       2.33     $ 12.75       132,286       2.33     $ 12.75  
          1,932,113       6.49     $ 5.99       1,364,260       6.49     $ 6.96  

The aggregate intrinsic value of outstanding options as of June 30, 2012 was $2.7 million, which represents the difference between the fair market value of the underlying shares based on the closing price of the Company’s common stock on June 29, 2012 of $4.58 and the aggregate exercise price of the options.
 
8. Fair Value Measurements
 
Assets and liabilities recorded at fair value on the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure the fair value.  Level inputs are as follows:

Level 1 – quoted prices in active markets for identical assets or liabilities.

Level 2 – other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.

Level 3 – significant unobservable inputs that reflect management’s best estimate of what market participants would use to price the assets or liabilities at the measurement date.

The following table summarizes fair value measurements by level at June 30, 2012 for assets and liabilities measured at fair value on a recurring basis:

(In thousands)
 
Level I
   
Level II
   
Level III
   
Total
 
Cash equivalents
  $ 11,045     $     $     $ 11,045  
Marketable securities
    15,068                   15,068  
Warrant liability
                19,155       19,155  

The following table summarizes fair value measurements by level at December 31, 2011 for assets and liabilities measured at fair value on a recurring basis:

(In thousands)
 
Level I
   
Level II
   
Level III
   
Total
 
Cash equivalents
  $ 17,073     $     $     $ 17,073  
Marketable securities
    18,058                   18,058  
Warrant liability
                6,739  

XFRA:CX5N CytRx Corp Quarterly Report 10-Q Filling

CytRx Corp XFRA:CX5N Stock - Get Quarterly Report SEC Filing of CytRx Corp XFRA:CX5N stocks, including company profile, shares outstanding, strategy, business segments, operations, officers, consolidated financial statements, financial notes and ownership information.

Content Partners
XFRA:CX5N CytRx Corp Quarterly Report 10-Q Filing - 6/30/2012
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Title |  Date |  Company |  Symbol |  Interest |  Popularity

Previous: XFRA:CX5N CytRx Corp Quarterly Report 10-Q Filing - 3/31/2012  |  Next: XFRA:CZ2 National Retail Properties Inc Insider Activity 3 Filing - 2/9/2012